Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Short-term Investments data on file, last reported at $120.8 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $120.8 million, up 511.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.8 million (up 511.97% YoY), and the FY2025 annual result was $39.5 million, down 3.68% from the prior year.
• Short-term Investments advanced to $120.8 million in Q1 2026 per IKT's latest filing, from $39.5 million in the prior quarter.
• Over five years, Short-term Investments peaked at $120.8 million in Q1 2026 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $24.5 million and a median of $19.0 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2025: Short-term Investments tumbled 90.51% in 2023, then surged 1575.91% in 2025.
• A 5-year view of Short-term Investments shows it stood at $15.9 million in 2022, then slumped by 74.23% to $4.1 million in 2023, then surged by 904.51% to $41.1 million in 2024, then slipped by 3.68% to $39.5 million in 2025, then surged by 205.47% to $120.8 million in 2026.
• Business Quant data shows IKT's Short-term Investments at $120.8 million in Q1 2026, $39.5 million in Q4 2025, and $39.1 million in Q3 2025.